GRI Bio, Inc. Files 8-K
Ticker: GRI · Form: 8-K · Filed: Jul 31, 2025 · CIK: 1824293
Sentiment: neutral
Topics: 8-K, corporate-filing
TL;DR
GRI Bio (GRI) filed an 8-K on 7/31/25. Standard update.
AI Summary
GRI Bio, Inc. filed an 8-K on July 31, 2025, reporting other events and financial statements. The company, formerly known as Vallon Pharmaceuticals, Inc., is incorporated in Delaware and headquartered in La Jolla, California.
Why It Matters
This filing provides an update on GRI Bio, Inc.'s corporate activities and financial reporting, which is important for investors to track company developments.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K, indicating no immediate significant events or changes.
Key Players & Entities
- GRI Bio, Inc. (company) — Registrant
- July 31, 2025 (date) — Date of Report
- Vallon Pharmaceuticals, Inc. (company) — Former Company Name
- La Jolla, CA (location) — Principal Executive Offices
FAQ
What is the primary purpose of this Form 8-K filing for GRI Bio, Inc.?
The Form 8-K filing on July 31, 2025, is for reporting 'Other Events' and 'Financial Statements and Exhibits'.
When was GRI Bio, Inc. previously known by another name?
GRI Bio, Inc. was formerly known as Vallon Pharmaceuticals, Inc., with a name change date of September 10, 2020.
Where is GRI Bio, Inc. headquartered?
GRI Bio, Inc.'s principal executive offices are located at 2223 Avenida de la Playa, #208, La Jolla, CA 92037.
What is the state of incorporation for GRI Bio, Inc.?
GRI Bio, Inc. is incorporated in Delaware.
What is the SEC file number for GRI Bio, Inc.?
The SEC file number for GRI Bio, Inc. is 001-40034.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 31, 2025 regarding GRI Bio, Inc. (GRI).